Phys Vivas · rheumatological
Antiphospholipid Syndrome — Viva Defence
DCE viva defence for Antiphospholipid Syndrome.
On this page
Study tools
Target exams
Antiphospholipid Syndrome Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Antiphospholipid Syndrome. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
References3ShowHide
- [1]Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria Arthritis Rheumatol, 2023.PMID 37635643
- [2]Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome Blood, 2018.PMID 30002145
- [3]Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults Ann Rheum Dis, 2019.PMID 31092409